Publications
Stay up to date with our literature reviews which are curated by experts to feature the most important publications released each month. Explore our publications for access to concise summary slides for your own use.
Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
Front Pharmacol. 2022;13:967317 DOI: 10.3389/fphar.2022.967317
A network meta-analysis has found that newer mineralocorticoid receptor antagonists (MRAs) appear to have greater efficacy in reducing urine albumin creatinine ratio (UACR) vs baseline than traditional MRAs in the treatment of diabetic kidney disease (DKD).
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
Front Pharmacol. 2022;13:935823 DOI: 10.3389/fphar.2022.935823
This meta-analysis investigated the effects of a range of doses of semaglutide in obese or overweight patients without diabetes. Other meta-analyses have investigated effects in patients with or without diabetes and assessed only the 2.4 mg-once-weekly dose of semaglutide.
Efficacy and Safety of Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial
Circ Heart Fail. 2022 DOI: 10.1161/CIRCHEARTFAILURE.122.010080
.
Keywords:
Efficacy and Safety of Once-Weekly Semaglutide in Adults With Overweight Or Obesity: A Meta-Analysis
Endocrine. 2022;75(3):718–24 doi: 10.1007/s12020-021-02945-1
Semaglutide QW was found to be superior to placebo in percentage change and absolute change in body weight. It also led to significant increases in proportions of patients achieving categorical weight reduction targets.